Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Techne (TECH) EBITDA Margin (2016 - 2026)

Bio-Techne has reported EBITDA Margin over the past 17 years, most recently at 13.54% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 1040.0% year-over-year to 13.54%; the TTM value through Dec 2025 reached 8.59%, down 279.0%, while the annual FY2025 figure was 7.53%, 592.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 13.54% at Bio-Techne, up from 11.75% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 3647.25% in Q3 2022 and troughed at 1.42% in Q2 2025.
  • A 5-year average of 197.69% and a median of 14.86% in 2022 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 362293bps in 2022 and later tumbled -363315bps in 2023.
  • Year by year, EBITDA Margin stood at 31.53% in 2021, then dropped by -22bps to 24.56% in 2022, then plummeted by -38bps to 15.34% in 2023, then crashed by -80bps to 3.14% in 2024, then surged by 331bps to 13.54% in 2025.
  • Business Quant data shows EBITDA Margin for TECH at 13.54% in Q4 2025, 11.75% in Q3 2025, and 1.42% in Q2 2025.